BG107611A - 4-, 5-, 6- и 7- индолови производни използвани залечение разстройства на централната нервна система - Google Patents

4-, 5-, 6- и 7- индолови производни използвани залечение разстройства на централната нервна система Download PDF

Info

Publication number: BG107611A
Authority: BG; Bulgaria
Prior art keywords: methyl; indole; piperazin; alkyl; group
Prior art date: 2000-08-18

Application number

BG107611A

Other languages

Bulgarian (bg)

English (en)

Inventor

Benny Bang-Andersen

Jan Kehler

Original Assignee

H.Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-18

Filing date

2003-03-06

Publication date

2003-12-31

2003-03-06 Application filed by H.Lundbeck A/S filed Critical H.Lundbeck A/S

2003-12-31 Publication of BG107611A publication Critical patent/BG107611A/bg

Links

229940054051 antipsychotic indole derivative Drugs 0.000 title description 2
-1 methylene dioxy group Chemical group 0.000 claims abstract description 109
150000001875 compounds Chemical class 0.000 claims abstract description 63
125000002252 acyl group Chemical group 0.000 claims abstract description 13
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 12
229910052736 halogen Inorganic materials 0.000 claims abstract description 12
150000002367 halogens Chemical class 0.000 claims abstract description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 12
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 12
125000001041 indolyl group Chemical group 0.000 claims abstract description 11
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims abstract description 11
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 10
125000003118 aryl group Chemical group 0.000 claims abstract description 10
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
239000001257 hydrogen Substances 0.000 claims abstract description 10
125000001424 substituent group Chemical group 0.000 claims abstract description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 9
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 8
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims abstract description 7
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 7
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 7
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 6
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims abstract description 5
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims abstract description 5
125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims abstract description 5
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 5
229910052799 carbon Inorganic materials 0.000 claims abstract description 5
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract description 4
125000003441 thioacyl group Chemical group 0.000 claims abstract description 4
125000004391 aryl sulfonyl group Chemical group 0.000 claims abstract description 3
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 13
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 11
208000028017 Psychotic disease Diseases 0.000 claims description 8
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
201000000980 schizophrenia Diseases 0.000 claims description 8
208000024891 symptom Diseases 0.000 claims description 8
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 7
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 6
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
208000012661 Dyskinesia Diseases 0.000 claims description 5
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 5
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 5
BDKHNYRNYWKAIO-UHFFFAOYSA-N 5-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2C=C3C=CNC3=CC=2)CC1 BDKHNYRNYWKAIO-UHFFFAOYSA-N 0.000 claims description 4
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
125000000623 heterocyclic group Chemical group 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
TWAMSXHFGNOVLT-UHFFFAOYSA-N 5-[(4-phenylpiperazin-1-yl)methyl]-1h-indole Chemical compound C=1C=C2NC=CC2=CC=1CN(CC1)CCN1C1=CC=CC=C1 TWAMSXHFGNOVLT-UHFFFAOYSA-N 0.000 claims description 3
JYNBMOGITRKBBH-UHFFFAOYSA-N 6-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C=C3NC=CC3=CC=2)CC1 JYNBMOGITRKBBH-UHFFFAOYSA-N 0.000 claims description 3
QZASZNJFIZLJFJ-UHFFFAOYSA-N 6-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2C=C3NC=CC3=CC=2)CC1 QZASZNJFIZLJFJ-UHFFFAOYSA-N 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
230000007278 cognition impairment Effects 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
125000005842 heteroatom Chemical group 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
BQEZHLDXTUPRJN-UHFFFAOYSA-N 5-[[4-(4-fluorophenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(F)=CC=C1N1CCN(CC=2C=C3C=CNC3=CC=2)CC1 BQEZHLDXTUPRJN-UHFFFAOYSA-N 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
FYBDIIFFALWSQI-UHFFFAOYSA-N 4-[4-(1h-indol-5-ylmethyl)piperazin-1-yl]phenol;5-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(O)=CC=C1N1CCN(CC=2C=C3C=CNC3=CC=2)CC1.COC1=CC=CC=C1N1CCN(CC=2C=C3C=CNC3=CC=2)CC1 FYBDIIFFALWSQI-UHFFFAOYSA-N 0.000 claims 1
AQLXZGBHDKWNMS-UHFFFAOYSA-N 5-[[4-(3,4-dimethoxyphenyl)piperazin-1-yl]methyl]-1h-indole;5-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound COC1=CC=CC(N2CCN(CC=3C=C4C=CNC4=CC=3)CC2)=C1.C1=C(OC)C(OC)=CC=C1N1CCN(CC=2C=C3C=CNC3=CC=2)CC1 AQLXZGBHDKWNMS-UHFFFAOYSA-N 0.000 claims 1
LBSDMKOUXCJRJQ-UHFFFAOYSA-N 5-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1H-indole 5-[4-(1H-indol-5-ylmethyl)piperazin-1-yl]-1H-indole Chemical compound N1C=CC2=CC(=CC=C12)N1CCN(CC1)CC=1C=C2C=CNC2=CC1.ClC1=CC=C(C=C1)N1CCN(CC1)CC=1C=C2C=CNC2=CC1 LBSDMKOUXCJRJQ-UHFFFAOYSA-N 0.000 claims 1
FPEYKUGYCPBUGB-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1CCN(CC1)CC1=CC=C2C=CN(C2=C1)C.ClC1=CC=C(C=C1)N1CCN(CC1)CC=1C=C2C=CN(C2=CC1)C Chemical compound ClC1=CC=C(C=C1)N1CCN(CC1)CC1=CC=C2C=CN(C2=C1)C.ClC1=CC=C(C=C1)N1CCN(CC1)CC=1C=C2C=CN(C2=CC1)C FPEYKUGYCPBUGB-UHFFFAOYSA-N 0.000 claims 1
HVKCXZKBKJNOMS-UHFFFAOYSA-N ClC=1C=C(C=CC1)N1CCN(CC1)CC=1C=C2C=CNC2=CC1.ClC1=C(C=CC=C1)N1CCN(CC1)CC=1C=C2C=CNC2=CC1.ClC1=CC=C(C=C1)C1CCN(CC1)CC=1C=C2C=CNC2=CC1 Chemical compound ClC=1C=C(C=CC1)N1CCN(CC1)CC=1C=C2C=CNC2=CC1.ClC1=C(C=CC=C1)N1CCN(CC1)CC=1C=C2C=CNC2=CC1.ClC1=CC=C(C=C1)C1CCN(CC1)CC=1C=C2C=CNC2=CC1 HVKCXZKBKJNOMS-UHFFFAOYSA-N 0.000 claims 1
NYBBBKYOORNLFA-UHFFFAOYSA-N ClC=1C=C(C=CC1Cl)N1CCN(CC1)CC=1C=C2C=CNC2=CC1.ClC1=C(C=CC=C1Cl)N1CCN(CC1)CC=1C=C2C=CNC2=CC1 Chemical compound ClC=1C=C(C=CC1Cl)N1CCN(CC1)CC=1C=C2C=CNC2=CC1.ClC1=C(C=CC=C1Cl)N1CCN(CC1)CC=1C=C2C=CNC2=CC1 NYBBBKYOORNLFA-UHFFFAOYSA-N 0.000 claims 1
125000003282 alkyl amino group Chemical group 0.000 claims 1
125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
230000019771 cognition Effects 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 44
229960003638 dopamine Drugs 0.000 abstract description 22
239000003446 ligand Substances 0.000 abstract description 7
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract description 5
125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 abstract description 3
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
238000000034 method Methods 0.000 description 11
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
239000000243 solution Substances 0.000 description 9
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
239000000654 additive Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000002464 receptor antagonist Substances 0.000 description 6
229940044551 receptor antagonist Drugs 0.000 description 6
239000002253 acid Substances 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
150000002431 hydrogen Chemical class 0.000 description 5
239000000203 mixture Substances 0.000 description 5
238000006722 reduction reaction Methods 0.000 description 5
HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 4
LFXXDQVEFFXFSD-UHFFFAOYSA-N 5-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C=C3C=CNC3=CC=2)CC1 LFXXDQVEFFXFSD-UHFFFAOYSA-N 0.000 description 4
208000018737 Parkinson disease Diseases 0.000 description 4
235000011054 acetic acid Nutrition 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
230000000561 anti-psychotic effect Effects 0.000 description 4
GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
239000007787 solid Substances 0.000 description 4
BQDJABPCSJJOJJ-UHFFFAOYSA-N 5-[[4-(4-methylphenyl)piperidin-1-yl]methyl]-1h-indole Chemical compound C1=CC(C)=CC=C1C1CCN(CC=2C=C3C=CNC3=CC=2)CC1 BQDJABPCSJJOJJ-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
229940099112 cornstarch Drugs 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
239000004031 partial agonist Substances 0.000 description 3
125000005493 quinolyl group Chemical group 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
125000001544 thienyl group Chemical group 0.000 description 3
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
KRVOJOCLBAAKSJ-RDTXWAMCSA-N (2R,3R)-nemonapride Chemical compound C1=C(Cl)C(NC)=CC(OC)=C1C(=O)N[C@H]1[C@@H](C)N(CC=2C=CC=CC=2)CC1 KRVOJOCLBAAKSJ-RDTXWAMCSA-N 0.000 description 2
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 2
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
JTSKVZMBTOWELA-UHFFFAOYSA-N 5-[[4-(2,3-dichlorophenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound ClC1=CC=CC(N2CCN(CC=3C=C4C=CNC4=CC=3)CC2)=C1Cl JTSKVZMBTOWELA-UHFFFAOYSA-N 0.000 description 2
GHVHEISIUPISMF-UHFFFAOYSA-N 5-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound COC1=CC=CC=C1N1CCN(CC=2C=C3C=CNC3=CC=2)CC1 GHVHEISIUPISMF-UHFFFAOYSA-N 0.000 description 2
CFAIBDJLYGXZKD-UHFFFAOYSA-N 5-[[4-(3,4-dichlorophenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCN(CC=2C=C3C=CNC3=CC=2)CC1 CFAIBDJLYGXZKD-UHFFFAOYSA-N 0.000 description 2
IJNCVBFCYRCRNM-UHFFFAOYSA-N 5-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound COC1=CC=CC(N2CCN(CC=3C=C4C=CNC4=CC=3)CC2)=C1 IJNCVBFCYRCRNM-UHFFFAOYSA-N 0.000 description 2
RJALIPYCWSQXNF-UHFFFAOYSA-N 6-[[4-(4-methylphenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(C)=CC=C1N1CCN(CC=2C=C3NC=CC3=CC=2)CC1 RJALIPYCWSQXNF-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
229960004170 clozapine Drugs 0.000 description 2
229960003368 croscarmellose sodium type a Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
125000005956 isoquinolyl group Chemical group 0.000 description 2
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
239000003176 neuroleptic agent Substances 0.000 description 2
230000000701 neuroleptic effect Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
229940085605 saccharin sodium Drugs 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
125000001425 triazolyl group Chemical group 0.000 description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
DISXUERFRLUXFM-UHFFFAOYSA-N 1-(1,2,3,6-tetrahydropyridin-4-yl)indole Chemical class C1NCCC(N2C3=CC=CC=C3C=C2)=C1 DISXUERFRLUXFM-UHFFFAOYSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
125000005955 1H-indazolyl group Chemical group 0.000 description 1
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
KAIRZPVWWIMPFT-UHFFFAOYSA-N 3-piperidin-4-yl-1h-indole Chemical class C1CNCCC1C1=CNC2=CC=CC=C12 KAIRZPVWWIMPFT-UHFFFAOYSA-N 0.000 description 1
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
GIOYFFPWJPAQMH-UHFFFAOYSA-N 5-[4-(1h-indol-5-ylmethyl)piperazin-1-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(CN2CCN(CC2)C=2C=C3C=CNC3=CC=2)=C1 GIOYFFPWJPAQMH-UHFFFAOYSA-N 0.000 description 1
PYXSRYXVSXMNFA-UHFFFAOYSA-N 5-[[4-(3-chlorophenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound ClC1=CC=CC(N2CCN(CC=3C=C4C=CNC4=CC=3)CC2)=C1 PYXSRYXVSXMNFA-UHFFFAOYSA-N 0.000 description 1
AIXQVYCHWMIPHZ-UHFFFAOYSA-N 5-[[4-(4-bromophenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(Br)=CC=C1N1CCN(CC=2C=C3C=CNC3=CC=2)CC1 AIXQVYCHWMIPHZ-UHFFFAOYSA-N 0.000 description 1
NMZVKLHZRUWGFV-UHFFFAOYSA-N 5-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1-methylindole Chemical compound C=1C=C2N(C)C=CC2=CC=1CN(CC1)CCN1C1=CC=C(Cl)C=C1 NMZVKLHZRUWGFV-UHFFFAOYSA-N 0.000 description 1
MAQRFMNYEBHRSR-UHFFFAOYSA-N 5-[[4-(4-fluorophenyl)piperidin-1-yl]methyl]-1h-indole Chemical compound C1=CC(F)=CC=C1C1CCN(CC=2C=C3C=CNC3=CC=2)CC1 MAQRFMNYEBHRSR-UHFFFAOYSA-N 0.000 description 1
SNRINYCCKNRZEH-UHFFFAOYSA-N 5-[[4-(4-iodophenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(I)=CC=C1N1CCN(CC=2C=C3C=CNC3=CC=2)CC1 SNRINYCCKNRZEH-UHFFFAOYSA-N 0.000 description 1
ALOCOCSTOMWABB-UHFFFAOYSA-N 5-[[4-(4-methylphenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(C)=CC=C1N1CCN(CC=2C=C3C=CNC3=CC=2)CC1 ALOCOCSTOMWABB-UHFFFAOYSA-N 0.000 description 1
VRYHLDYOQRWABX-UHFFFAOYSA-N 6-[[4-(4-methylphenyl)piperidin-1-yl]methyl]-1h-indole Chemical compound C1=CC(C)=CC=C1C1CCN(CC=2C=C3NC=CC3=CC=2)CC1 VRYHLDYOQRWABX-UHFFFAOYSA-N 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
MTGBBEOZVYSVKC-UHFFFAOYSA-N ClC1=C(C=CC=C1)N1CCN(CC1)CC=1C=C2C=CNC2=CC1.ClC1=CC=C(C=C1)C1CCN(CC1)CC=1C=C2C=CNC2=CC1.FC1=CC=C(C=C1)N1CCN(CC1)CC=1C=C2C=CNC2=CC1 Chemical compound ClC1=C(C=CC=C1)N1CCN(CC1)CC=1C=C2C=CNC2=CC1.ClC1=CC=C(C=C1)C1CCN(CC1)CC=1C=C2C=CNC2=CC1.FC1=CC=C(C=C1)N1CCN(CC1)CC=1C=C2C=CNC2=CC1 MTGBBEOZVYSVKC-UHFFFAOYSA-N 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
125000005129 aryl carbonyl group Chemical group 0.000 description 1
125000003943 azolyl group Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
239000002775 capsule Substances 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
230000003930 cognitive ability Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical compound CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
229940052760 dopamine agonists Drugs 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019439 ethyl acetate Nutrition 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
IENZCGNHSIMFJE-UHFFFAOYSA-N indole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC=CC2=C1 IENZCGNHSIMFJE-UHFFFAOYSA-N 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
235000020094 liqueur Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
150000002829 nitrogen Chemical class 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
238000006053 organic reaction Methods 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
WUHLVXDDBHWHLQ-UHFFFAOYSA-N pentazole Chemical compound N=1N=NNN=1 WUHLVXDDBHWHLQ-UHFFFAOYSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000012552 review Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000020354 squash Nutrition 0.000 description 1
230000005477 standard model Effects 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
238000001214 thermospray mass spectrometry Methods 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
238000011491 transcranial magnetic stimulation Methods 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

BG107611A 2000-08-18 2003-03-06 4-, 5-, 6- и 7- индолови производни използвани залечение разстройства на централната нервна система BG107611A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200001229		2000-08-18
PCT/DK2001/000547 WO2002016349A1 (fr)	2000-08-18	2001-08-17	Derives 4-, 5-, 6- et 7-indoliques utiles dans le traitement de troubles du systeme nerveux central

Publications (1)

Publication Number	Publication Date
BG107611A true BG107611A (bg)	2003-12-31

Family

ID=8159658

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107611A BG107611A (bg)	2000-08-18	2003-03-06	4-, 5-, 6- и 7- индолови производни използвани залечение разстройства на централната нервна система

Country Status (29)

Country	Link
US (2)	US6958338B2 (fr)
EP (1)	EP1309586B1 (fr)
JP (1)	JP2004506731A (fr)
KR (1)	KR20030022363A (fr)
CN (1)	CN1243750C (fr)
AR (1)	AR030357A1 (fr)
AT (1)	ATE321040T1 (fr)
AU (2)	AU7961101A (fr)
BG (1)	BG107611A (fr)
BR (1)	BR0113452A (fr)
CA (1)	CA2419266A1 (fr)
CZ (1)	CZ2003461A3 (fr)
DE (1)	DE60118205T2 (fr)
DK (1)	DK1309586T3 (fr)
EA (1)	EA006155B1 (fr)
ES (1)	ES2257424T3 (fr)
HR (1)	HRP20030052A2 (fr)
HU (1)	HUP0302777A2 (fr)
IL (1)	IL154051A0 (fr)
IS (1)	IS6694A (fr)
MX (1)	MXPA03000838A (fr)
NO (1)	NO20030522D0 (fr)
NZ (1)	NZ523786A (fr)
PL (1)	PL363309A1 (fr)
PT (1)	PT1309586E (fr)
SK (1)	SK3212003A3 (fr)
UA (1)	UA74837C2 (fr)
WO (1)	WO2002016349A1 (fr)
ZA (1)	ZA200300562B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2520567A3 (fr) *	2006-02-23	2012-12-12	Shionogi & Co., Ltd.	Dérivés d'hétérocycle contenant de l'azote substitués avec un groupe cyclique
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
NZ596889A (en)	2006-04-07	2013-06-28	Vertex Pharma	Use of amide indole derivatives as modulators of ATP-binding cassette transporters
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
TWI404702B (zh) *	2007-08-31	2013-08-11	Lundbeck & Co As H	兒茶酚胺衍生物和其前藥
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2745977C2 (ru)	2010-04-22	2021-04-05	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения циклоалкилкарбоксамидо-индольных соединений
AU2013290444B2 (en)	2012-07-16	2018-04-26	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
JO3425B1 (ar)	2013-07-15	2019-10-20	Novartis Ag	مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
SG10201913575VA (en)	2014-04-15	2020-02-27	Vertex Pharma	Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3421641A1 (de) *	1984-06-09	1985-12-12	Merck Patent Gmbh, 6100 Darmstadt	Indolderivate
MX173362B (es) *	1987-03-02	1994-02-23	Pfizer	Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) *	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
AU6215594A (en) *	1993-03-18	1994-10-11	Merck Sharp & Dohme Limited	Indole derivatives as dopamine d4 antagonists
JPH09512542A (ja) *	1994-04-28	1997-12-16	メルクシヤープエンドドームリミテツド	Ｄ▲下４▼リセプタ拮抗剤としてのベンゾフラン誘導体
DE19500689A1 (de)	1995-01-12	1996-07-18	Merck Patent Gmbh	Indolpiperidin-Derivate
GB9520731D0 (en) *	1995-10-10	1995-12-13	Merck Sharp & Dohme	Therapeutic agents
GB9604036D0 (en) *	1996-02-26	1996-04-24	Merck Sharp & Dohme	Therapeutic agents
WO1999037304A1 (fr) *	1998-01-27	1999-07-29	Aventis Pharmaceuticals Products Inc.	COMPOSES OXOAZAHETEROCYCLYLE SUBSTITUES INHIBITEURS DU FACTEUR Xa
DZ3223A1 (fr) *	1999-10-19	2001-04-26	Merck & Co Inc	Inhibiteurs de tyrosine kinases
US6727264B1 (en) *	2001-07-05	2004-04-27	Synaptic Pharmaceutical Corporation	Substituted anilinic piperidines as MCH selective antagonists

2001
- 2001-08-15 AR ARP010103899A patent/AR030357A1/es not_active Application Discontinuation
- 2001-08-17 CZ CZ2003461A patent/CZ2003461A3/cs unknown
- 2001-08-17 AU AU7961101A patent/AU7961101A/xx active Pending
- 2001-08-17 NZ NZ523786A patent/NZ523786A/en unknown
- 2001-08-17 PL PL01363309A patent/PL363309A1/xx not_active Application Discontinuation
- 2001-08-17 DK DK01957788T patent/DK1309586T3/da active
- 2001-08-17 HU HU0302777A patent/HUP0302777A2/hu unknown
- 2001-08-17 CA CA002419266A patent/CA2419266A1/fr not_active Abandoned
- 2001-08-17 DE DE60118205T patent/DE60118205T2/de not_active Expired - Fee Related
- 2001-08-17 JP JP2002521450A patent/JP2004506731A/ja not_active Withdrawn
- 2001-08-17 WO PCT/DK2001/000547 patent/WO2002016349A1/fr not_active Ceased
- 2001-08-17 BR BR0113452-3A patent/BR0113452A/pt not_active IP Right Cessation
- 2001-08-17 UA UA2003010504A patent/UA74837C2/uk unknown
- 2001-08-17 IL IL15405101A patent/IL154051A0/xx unknown
- 2001-08-17 KR KR10-2003-7001687A patent/KR20030022363A/ko not_active Ceased
- 2001-08-17 CN CNB018142400A patent/CN1243750C/zh not_active Expired - Fee Related
- 2001-08-17 AU AU2001279611A patent/AU2001279611B2/en not_active Ceased
- 2001-08-17 HR HR20030052A patent/HRP20030052A2/xx not_active Application Discontinuation
- 2001-08-17 ES ES01957788T patent/ES2257424T3/es not_active Expired - Lifetime
- 2001-08-17 EP EP01957788A patent/EP1309586B1/fr not_active Expired - Lifetime
- 2001-08-17 AT AT01957788T patent/ATE321040T1/de not_active IP Right Cessation
- 2001-08-17 MX MXPA03000838A patent/MXPA03000838A/es active IP Right Grant
- 2001-08-17 EA EA200300278A patent/EA006155B1/ru not_active IP Right Cessation
- 2001-08-17 SK SK321-2003A patent/SK3212003A3/sk unknown
- 2001-08-17 PT PT01957788T patent/PT1309586E/pt unknown
2003
- 2003-01-20 IS IS6694A patent/IS6694A/is unknown
- 2003-01-21 ZA ZA200300562A patent/ZA200300562B/en unknown
- 2003-02-03 NO NO20030522A patent/NO20030522D0/no not_active Application Discontinuation
- 2003-02-04 US US10/359,052 patent/US6958338B2/en not_active Expired - Fee Related
- 2003-03-06 BG BG107611A patent/BG107611A/bg unknown
2005
- 2005-09-01 US US11/219,544 patent/US7105543B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA200300278A1 (ru)	2003-06-26
HRP20030052A2 (en)	2005-02-28
DK1309586T3 (da)	2006-07-10
MXPA03000838A (es)	2003-06-06
AU7961101A (en)	2002-03-04
PT1309586E (pt)	2006-06-30
NZ523786A (en)	2005-07-29
CN1243750C (zh)	2006-03-01
NO20030522L (no)	2003-02-03
DE60118205T2 (de)	2006-11-02
KR20030022363A (ko)	2003-03-15
PL363309A1 (en)	2004-11-15
UA74837C2 (en)	2006-02-15
HUP0302777A2 (hu)	2003-12-29
CN1447806A (zh)	2003-10-08
US6958338B2 (en)	2005-10-25
EA006155B1 (ru)	2005-10-27
NO20030522D0 (no)	2003-02-03
US20030166665A1 (en)	2003-09-04
US20060004022A1 (en)	2006-01-05
AU2001279611B2 (en)	2006-08-10
IS6694A (is)	2003-01-20
SK3212003A3 (en)	2003-07-01
AR030357A1 (es)	2003-08-20
ATE321040T1 (de)	2006-04-15
US7105543B2 (en)	2006-09-12
JP2004506731A (ja)	2004-03-04
IL154051A0 (en)	2003-07-31
CA2419266A1 (fr)	2002-02-28
ES2257424T3 (es)	2006-08-01
ZA200300562B (en)	2004-08-23
BR0113452A (pt)	2003-07-15
WO2002016349A1 (fr)	2002-02-28
EP1309586B1 (fr)	2006-03-22
DE60118205D1 (de)	2006-05-11
HK1059438A1 (en)	2004-07-02
CZ2003461A3 (cs)	2003-05-14
EP1309586A1 (fr)	2003-05-14

Publication	Publication Date	Title
SK9342003A3 (en)	2003-10-07	3-Indoline derivatives useful in the treatment of psychiatric and neurologic disorders
BG107611A (bg)	2003-12-31	4-, 5-, 6- и 7- индолови производни използвани залечение разстройства на централната нервна система
AU2001279611A1 (en)	2002-05-30	4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders
US6890916B2 (en)	2005-05-10	Indole derivatives useful for the treatment of CNS disorders
AU2001273881A1 (en)	2002-03-14	Indole derivatives useful for the treatment of CNS disorders
SK286701B6 (sk)	2009-03-05	Indolové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
AU2001281738A1 (en)	2002-05-02	Indole derivatives useful for the treatment of cns disorders
SK1092003A3 (en)	2003-05-02	Indole derivatives useful for the treatment of CNS disorders
EP1468996B1 (fr)	2007-09-26	Derivés d'indole pour le traitement des maladies du système nerveux central
MXPA02012568A (es)	2003-04-10	Derivados de indol utiles para el tratameinto de enfermedades del sistema nervioso central.
EP1214312A1 (fr)	2002-06-19	Indoles substitues 5-aminoalkyle et 5-aminocarbonyle
SK402003A3 (en)	2003-07-01	Indole derivatives, pharmaceutical composition comprising same and their use
MXPA02012149A (en)	2008-10-03	Indole derivatives useful for the treatment of cns disorders